ZIVO Bioscience and NutriQuest LLC Conclude Two Poultry Studies With Positive Results, Continue to Move Forward With FDA Compliance

ZIVO Bioscience and NutriQuest LLC Conclude Two Poultry Studies With Positive Results, Continue to Move Forward With FDA Compliance

KEEGO HARBOR, Mich., Sept. 19, 2017 (GLOBE NEWSWIRE) -- ZIVO Bioscience, Inc. (OTCMKTS:ZIVO) a biotech/agtech R&D company engaged in the commercialization of nutritional and medicinal products derived from proprietary algal strains, announces results from two poultry studies designed and supervised by animal nutrition strategic partner NutriQuest, LLC. The two studies, focused on broiler production, provided encouraging results on the benefits of including a proprietary strain of dried algal biomass in broiler feed under several real-world challenges. This development advances the prospective market entry of a ZIVO phytogenic feed ingredient for poultry applications.

Toward that end, ZIVO is currently finalizing compliance for its algal biomass as a food ingredient, and simultaneously working to advance compliance as a poultry feed ingredient, per the current regulatory paradigm. The Company has looked to the end of 2017/early 2018 as the target timing to convene a GRAS panel review for self-affirmation in humans, to be followed closely by an NDI (New Dietary Ingredient) application for humans. Regulatory approval for a poultry feed ingredient is expected in the first half of 2018 and the Company is now working on plans to scale up production to meet the market needs of the broiler industry.

NutriQuest has scheduled additional studies for this fall to further define use rates, application and the full potential value of the ZIVO algal ingredient. NutriQuest’s research is focused on developing applications that significantly enhance poultry producers’ position and profitability. The ZIVO/NutriQuest partnership will help speed entry into global markets and ramp up the adoption rate of the ZIVO phytogenic ingredient with producers.  NutriQuest has built a successful solutions-oriented business with global reach, providing the credibility and market visibility that only a well-established brand name in animal health and nutrition can command.

About NutriQuest, LLC

NutriQuest® is a team of industry-leading animal experts serving producers by delivering targeted breakthrough solutions. NutriQuest is privileged to have a leadership role in the animal industry and driven by a strong sense of stewardship for animal production. Through collaboration with industry participants, technology providers and customers, NutriQuest is continually working on behalf of animal producers to fill critical needs and provide a high level of value.

With a large US swine customer base and growth in the poultry, ruminant and international sectors, the NutriQuest portfolio of solutions includes research-based feed additives, protein technologies, nutritional monitoring services, water quality products, and humane euthanasia technology, among others that improve performance and cost position to the producer. With world-class internal research capabilities, NutriQuest animal nutrition and production experts scrutinize products and technologies to ensure that all NutriQuest solutions meet or exceed rigorous standards for efficacy, return on investment and practicality.

About ZIVO Bioscience, Inc.

ZIVO Bioscience, Inc. (OTCMKTS:ZIVO) is a Michigan-based biotech company engaged in the investigation of the health and nutritional benefits of bioactive compounds derived from its proprietary algal cultures, and the development of natural bioactive compounds for use as dietary supplements and food ingredients, as well as biologically derived and synthetic candidates for medicinal and pharmaceutical applications in humans and animals, specifically focused on autoimmune and inflammatory response modulation.  For project updates please visit: www.zivobioscience.com.

Safe Harbor Statement

Except for any historical information, the matters discussed in this press release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements involve risks and uncertainties. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including the timing of completion of a trial, actual future clinical trial results being different than the results the company has obtained to date, and the company's ability to secure funding. Such statements are subject to a number of assumptions, risks and uncertainties. Readers are cautioned that such statements are not guarantees of future performance and those actual results or developments may differ materially from those set forth in the forward-looking statements. The company undertakes no obligation to publicly update or revise forward-looking statements, whether as a result of new information or otherwise. 

Investor Relations
(248) 452 9866 ext 150
ZIVO Bioscience, Inc. 

Primary Logo

Source: Zivo Bioscience, Inc.